JOHANNESBURG, Sept 2 (Reuters) – South Africa’s Aspen Pharmacare reported on Wednesday a 22% rise in normalised earnings, supported by strong momentum in its commercial pharmaceuticals unit, which was the main driver of growth in the reporting period.
Normalised headline earnings per share (HEPS) rose to 801.5 cents in the year ended June 30 from 659.2 cents in the previous year. In constant exchange rate HEPS rose 28%.
(Reporting by Nqobile Dludla, Editing by Louise Heavens)
Comments